[Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
The aim of study was to analyze the results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease (3-5 stage of CKD) in predialysis period.


METHODS
In the study the results of anemia treatment with darbepoetin alfa and erythropoietin beta were analyzed in respectively 35 and 20 patients during 11 months, and its influence on blood pressure and the rate of progression of chronic kidney disease. After 2 months of darbepoetin alfa treatment 10 mg/month and after 4 months of darbepoetin alfa treatment 20 mg/month the hemoglobin target serum levels in male and female patients were reached. In 3 patients the hemoglobin serum level was increased over 13 g/dl and was stable up to the end of treatment. During 11 months observation the value of blood pressure was not changed. Similarly, a creatinine serum level was stable in females but increased in males. Therapy with darbepoetin alfa was well tolerated, however some patients were complained for subcutaneous injection pain.


RESULTS
After erythropoietin beta treatment 2000 IU/week the hemoglobin target level in serum was achieved in 3 females after 9 months and 7 males after 6 months. In 3 patients, in one male after 6 months and two females after 8 months the hemoglobin serum levels were increased over 13 g/dl and was stable up to the end of treatment.


CONCLUSIONS
During 11 months of observation blood pressure was not changed but a creatinine serum level was increased in females and in males. Erythropoietin beta was well tolerated and injection pain was smaller compared to darbepoetin alfa.
Wanic-Kossowska
Maria
M
Klinika i Katedra Nefrologii, Transplantologii i Chorób Wewnetrznych UM w Poznaniu. marwankos@wp.pl
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D000068256:Darbepoetin alfa; D018450:Disease Progression; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous / Q000009:adverse effects; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D016896:Treatment Outcome
D006454:Hemoglobins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D003404:Creatinine